ZA202107077B - Anti-cd6 antibody compositions and methods for treating lupus - Google Patents

Anti-cd6 antibody compositions and methods for treating lupus

Info

Publication number
ZA202107077B
ZA202107077B ZA2021/07077A ZA202107077A ZA202107077B ZA 202107077 B ZA202107077 B ZA 202107077B ZA 2021/07077 A ZA2021/07077 A ZA 2021/07077A ZA 202107077 A ZA202107077 A ZA 202107077A ZA 202107077 B ZA202107077 B ZA 202107077B
Authority
ZA
South Africa
Prior art keywords
methods
antibody compositions
treating lupus
lupus
treating
Prior art date
Application number
ZA2021/07077A
Other languages
English (en)
Inventor
Stephen Connelly
Krishna Polu
Chandra Mohan
Original Assignee
Equillium Inc
Univ Houston System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equillium Inc, Univ Houston System filed Critical Equillium Inc
Publication of ZA202107077B publication Critical patent/ZA202107077B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2021/07077A 2019-02-26 2021-09-22 Anti-cd6 antibody compositions and methods for treating lupus ZA202107077B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810628P 2019-02-26 2019-02-26
US201962933294P 2019-11-08 2019-11-08
PCT/US2020/019990 WO2020176682A1 (en) 2019-02-26 2020-02-26 Anti-cd6 antibody compositions and methods for treating lupus

Publications (1)

Publication Number Publication Date
ZA202107077B true ZA202107077B (en) 2023-07-26

Family

ID=70009403

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/07077A ZA202107077B (en) 2019-02-26 2021-09-22 Anti-cd6 antibody compositions and methods for treating lupus

Country Status (12)

Country Link
US (1) US20220143140A1 (cg-RX-API-DMAC7.html)
EP (1) EP3930751A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022521973A (cg-RX-API-DMAC7.html)
CN (1) CN113490511B (cg-RX-API-DMAC7.html)
AU (1) AU2020229830A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016967A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131299A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010283A (cg-RX-API-DMAC7.html)
PH (1) PH12021551994A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109118XA (cg-RX-API-DMAC7.html)
WO (1) WO2020176682A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107077B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
IL303290A (en) * 2020-12-04 2023-07-01 Equillium Inc Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells
EP4533094A4 (en) * 2022-05-25 2026-05-06 Univ Houston System METHODS AND SYSTEMS FOR RISK STRATIFICATION AND BLADDER CANCER MANAGEMENT
TWI869873B (zh) * 2023-06-05 2025-01-11 中國醫藥大學 一種檢測一個體罹患單純復發性風濕病的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
MY154819A (en) 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
WO2012133047A1 (ja) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
EP2726879B1 (en) * 2011-07-01 2022-10-19 Beckman Coulter, Inc. Requlatory t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
CA2866612C (en) * 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
US10620201B2 (en) * 2014-01-20 2020-04-14 Pad 4 Di Maria Adele Silvia Denegri S.A.S. In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
SG11201808625QA (en) * 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
WO2017214452A1 (en) * 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법

Also Published As

Publication number Publication date
PH12021551994A1 (en) 2022-08-15
SG11202109118XA (en) 2021-09-29
JP2022521973A (ja) 2022-04-13
BR112021016967A2 (pt) 2021-11-23
MX2021010283A (es) 2021-09-30
CA3131299A1 (en) 2020-09-03
US20220143140A1 (en) 2022-05-12
WO2020176682A1 (en) 2020-09-03
AU2020229830A1 (en) 2021-09-16
CN113490511B (zh) 2024-07-09
EP3930751A1 (en) 2022-01-05
CN113490511A (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL286350A (en) Preparations and methods for the treatment of cancer
IL288914A (en) Preparations and methods for the treatment of cancer
IL279265A (en) Compounds and methods for treating immune thrombocytopenia
IL285886A (en) Preparations and methods for the treatment of laminopathy
ZA202104870B (en) Methods and compositions for treating cancer
IL290840A (en) Preparations and methods for altering cd123
SG11202109118XA (en) Anti-cd6 antibody compositions and methods for treating lupus
SG11202012435UA (en) Compositions and methods for treating cancer
IL285796A (en) Methods and preparations for the treatment of cancer
IL287961A (en) Compositions and methods for treating lung conditions associated with biophiles
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
IL287982A (en) Preparations and methods for the treatment of cancer
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
ZA202005320B (en) Anti cd6 antibodies for treating severe asthma
SG11202106857VA (en) Compositions and methods for inhibiting hmgb1 expression
IL277463A (en) Vehicles and methods for treating itch
PT3529274T (pt) Um anticorpo monoclonal e um método de utilização para o tratamento de lúpus
IL282948B2 (en) Cancer treatment preparations and methods
EP3883588A4 (en) COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS
IL286153A (en) Methods and preparations for the treatment of cancer
EP3801620A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATITIS
EP3773585A4 (en) Compositions and methods for treating cancer
IL288563A (en) Ethods and compositions for treating autoimmune diseases
IL277332A (en) Preparations and methods for treating severe constipation